company background image
SCYX logo

SCYNEXIS NasdaqGM:SCYX Stock Report

Last Price

US$1.95

Market Cap

US$73.7m

7D

-4.4%

1Y

-31.6%

Updated

23 Jun, 2024

Data

Company Financials +

SCYNEXIS, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SCYNEXIS
Historical stock prices
Current Share PriceUS$1.95
52 Week HighUS$3.87
52 Week LowUS$1.35
Beta1.54
11 Month Change-17.02%
3 Month Change36.36%
1 Year Change-31.58%
33 Year Change-75.47%
5 Year Change-85.11%
Change since IPO-97.83%

Recent News & Updates

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Apr 13
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Mar 15
Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Shareholder Returns

SCYXUS PharmaceuticalsUS Market
7D-4.4%1.0%0.5%
1Y-31.6%17.5%23.7%

Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 17.5% over the past year.

Return vs Market: SCYX underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is SCYX's price volatile compared to industry and market?
SCYX volatility
SCYX Average Weekly Movement14.0%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement5.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: SCYX's share price has been volatile over the past 3 months.

Volatility Over Time: SCYX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199929David Angulowww.scynexis.com

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.

SCYNEXIS, Inc. Fundamentals Summary

How do SCYNEXIS's earnings and revenue compare to its market cap?
SCYX fundamental statistics
Market capUS$73.67m
Earnings (TTM)US$101.33m
Revenue (TTM)US$140.38m

0.7x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCYX income statement (TTM)
RevenueUS$140.38m
Cost of RevenueUS$15.49m
Gross ProfitUS$124.90m
Other ExpensesUS$23.57m
EarningsUS$101.33m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.68
Gross Margin88.97%
Net Profit Margin72.18%
Debt/Equity Ratio16.7%

How did SCYX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.